Sorrento to Initiate P-I Study of STI-1499 in COVID-19 Positive Patients

 Sorrento to Initiate P-I Study of STI-1499 in COVID-19 Positive Patients

Sorrento to Initiate P-I Study of STI-1499 in COVID-19 Positive Patients

Shots:

  • Sorrento receives the US FDA’s clearance to proceed P-I clinical study of STI-1499 (COVI-GUARD) in hospitalized COVID-19 patients. The company receives the FDA’s notice to proceed the patient enrollment
  • The trial is anticipated to enroll rapidly and is expected to be followed by large trials targeting a potential EUA submission as early as before the end of 2020. STI-1499 has demonstrated 100% in vitro neutralizing effect against SARS-CoV-2 in preclinical studies
  • The highest proposed dose (200mg/patient) in P-I study is a lower dose than currently being tested for other known SARS-CoV-2 targeted Abs or Ab cocktails in studies. Sorrento has initiated cGMP manufacturing to produce 50,000 doses in anticipation of a EUA

Click here ­to­ read full press release/ article | Ref: Sorrento | Image: Euractive

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post